addressed the urgent need for multimodal strategies in non-small cell lung cancer (NSCLC) treatment through the synthesis and application of multifunctional bionic nanomedicines (APSNM), particularly targeting the limited efficacy of traditional PD-L1 antibody immunotherapy due to insufficient tumor accumulation and persistent intracellular PD-L1 signaling. The gene discussed is CD274; the disease is neoplasm.